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Patients with symptomatic tight carotid stenosis have an increased short-time risk of stroke and an increased long-term risk
of ischaemic vascular events compared with the general population. The aim of this study is to assess the safety, efficacy, and
limitations of urgent CEA or CAS, in patients with carotid stenosis greater than 70% and clinically characterized by recurrent
TIA or brain damage following a stroke (<2.5 cm). This study involved 28 patients divided into two groups. Group A consisted of
sixteen patients who had undergone CEA, and group B consisted of twelve patients who had undergone CAS. Primary endpoints
were mortality, neurological morbidity (by NIHSS) and postoperative hemorrhagic cerebral conversion, at 30 days. Ten patients
(62.5%) of group A experienced an improvement in their initial neurological deficit while in 4 cases (26%) the deficit remained
stable. Two cases of neurologic mortality are presented. At 1 month, 9 patients (75%) of group B experienced an improvement in
their initial neurological deficit while 3 patients (25%) had a neurological impairment. Urgent or deferred surgical or endovascular
treatment have a satisfactory outcome considering the profile in very high-risk patient population. Otherwise in selected patients
CEA seems to be preferred to CAS.
1. Introduction
Ipsilateral >50% carotid stenosis is found in about 10% of
carotid territory ischaemic strokes and in about 15% of TIAs
(transitory ischemic attack), and is associated with a partic-
ularly high risk of recurrent stroke [1–3], both in the acute
phase and long term [4]. Recent studies showed that 4−20%
of TIA patients will have a stroke within 90 days after a TIA,
half within the first 2 days [5, 6]. Reanalysis of controlled
trials of CEA (carotid endarterectomy) indicated that surgery
conferred the greatest benefit when performed in the first
2 weeks following the index symptoms, perhaps as early as
48 h after the index event [7, 8]. Delaying intervention quite
probably means that patients are better selected and this
could guarantee better early outcomes, but this delay can
also result in an interval stroke rate of 9–15% [9]. In the
past few years CAS (carotid artery stenting) has emerged as
a treatment alternative to CEA. A recent study found that
early CAS might be associated with an increased risk for
stroke and death [10]. In fact CAS, in the acute stage, remains
challenging because of the limited therapeutic window and
risk of hyperperfusion syndrome or cerebral hemorrhagic
infarction after revascularization [11]. The real goal of early
treatment is to stop the plaque embolization from a vulnera-
ble lesion at the carotid bifurcation [12]. Another important
question is: is there a patient at higher risk of neurological
impairment in the short term? The ABCD2 score is a
prognostic score that we, retrospectively, used to validate
our practice [13]. This retrospective study investigates the
safety, efficacy, and limitations of urgent CEA or CAS for
symptomatic patients with recent first or recurrent TIA or
minor stroke, bearing severe carotid artery stenosis.
2. Methods
This was a retrospective review of two groups of patients:
group A, with patients treated with open surgery, and group
B, with patients treated with endovascular technique. In our
institution the guidelines of treatment do not consider BMT,
so a control group is not available. All patients were observed
in emergency department (ED) by a neurologist and a
vascular surgeon. Cerebral CT scan or MRI was performed in
all patients before and after the treatment. If CT scan or MRI
ruled out hemorrhagic events, intravenous heparin therapy
was administered immediately. Demographic data, including
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Table 1: Comparison of clinical characteristics and results of clinical workup between patients in surgical group and those in endovascular
group.
Parameter
Surgical group
(n = 16)
Endovascular group
(n = 12)
Sex
Female 5 3
Male 11 9
Age (y)
Mean 70 75
Vascular risk factors
Hypertension 7 (43) 5 (41)
Current cigarette smoking 8 (50) 7 (58)
Diabetes mellitus 6 (37) 8 (66)
Hypercholesterolemia 9 (56) 6 (50)
Heart disease 3 (18) 5 (41)
History of amaurosis fugax, retinal infarct, transient ischemic attack, or stroke 4 (25) 3 (25)
Neurological status during treatment
Asymptomatic (TIA) 7 (44) 3 (25)
Symptomatic stable (minor stroke) 3 (18) 5 (41)
Symptomatic stable (major stroke) 6 (37) 4 (33)
Median NIHSS score 7.4 4.4
Time from onset of symptoms to treatment
Emergency (<24 h) 13 (81) 11 (91)
Urgency (<7 days) 3 (18) 1 (9)
Early neurological results
Improvements (>1 NIHSS) 10 (63) 9 (75)
Stable 4 (25) —
Impairment (>1 NIHSS) 2 (12.5) 3 (25)
Early death 2 (12.5) —
New ischemic lesions p.o. — 3 (25)
Cerebral hemorrhage 2 (12.5) —
Note: numbers in parentheses are percentages.
age, sex, symptom details, risk factors, medications, and
operative data were collected for all patients. The National
Institutes of Health Stroke Scale (NIHSS) was used for
neurological assessment; the score was recorded routinely
before, 24 h, and 3 days after treatment. Ecocolor Doppler
(ECD) was performed in all patients to evaluate the carotid
bifurcation (type of plaque and haemodynamics of the
lesion). Anatomy of aortic arch and supra-aortic trunks were
also evaluated with angio-CT o MRI in all cases. All patients
underwent transcranial Doppler (TCD) before surgery to
evaluate the presence and frequency of microembolic signal
(MES), to detect the middle cerebral artery (MCA) patency,
and to test the intraoperative clamping tolerance.
The emergency treatment was performed in patients with
very tight stenosis and clinically characterized by recurrent
TIA or stroke with little cerebral damage (<2.5 cm). For
patients with different clinical picture, we had the possibility
to keep time to prepare them in the best way for surgery.
Only one patient was undergoing preoperative
fibrinolytic therapy and then she died of haemorrhagic
postoperative cerebral infarction. All patients received in-
travenous heparin before carotid intervention.
Patients were excluded if cerebral ischemic lesions were
greater than 2.5 cm, if there was loss of consciousness, if there
were signs of intracranial hemorrhage, and if the patients or
family did not give informed consent.
Group A. Sixteen patients who had undergone CEA after
TIA, minor or major stroke, from October 2004 to August
2010, were identified. Clinical characteristics of this group
of patients are shown in Table 1. In 13 patients a patch
angioplasty, in 2 cases a direct suture of arteriotomy, and in
1 case an eversion CEA were performed.
A Pruitt Inahara shunt has been used in 8 patients. For
interventions performed under general anaesthesia, it has
been placed when, during clamping, the DTC signal showed
a reduction of 2/3 of middle cerebral artery flow, while for
interventions performed under local anaesthesia, it has been
used when, during clamping, a clinical deficit appeared. In
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Table 2: Nicolaides plaque classification.
Plaque Morphologic characterization
Type 1 Uniformly echolucent plaque
Type 2
Predominantly echolucent plaques with less than 50%
echogenic areas
Type 3
Predominantly echogenic plaques with less than 50%
echolucent areas
Type 4 Uniformly echogenic plaques
Type 5
Could not be classified (heavy calcification and acoustic
shadows)
suitable patients CEA was undertaken on the next available
operating room, with a preference for local anaesthesia.
Group B. Twelve patients who had undergone CAS after TIA
minor or major stroke, from September 2004 to February
2011, were identified. Clinical characteristics of this group
of patients are shown in Table 1. The cerebral protection was
performed in all cases with distal embolic protection device.
In 8 cases the CAS was performed with femoral access, in
4 patients a cervical cutdown was used. In suitable patients
CAS was undertaken on the next available operating room
by vascular surgeon, in local anaesthesia.
CEA contraindications were high-risk patients, hostile
neck, and high bifurcation. CAS contraindications were
difficult access anatomy, very tight stenosis, and soft or very
calcified lesions (Table 2) [14].
In absence of contraindications for CAS or CEA the op-
erative technique was chosen according to surgeon’s prefer-
ence.
All patient were observed in critical care unit after oper-
ation.
Retrospectively we applied ABCD2 score [13] to validate
or not our therapeutic strategy (the appendix).
Patients were followed up for 30 days after their clinical
presentation. Stroke, TIAs, deaths, and hospitalization for
cardiovascular events were identified for all patients. The
primary outcome was recurrent TIA or minor stroke or
stroke occurring within 30 days of TIA or minor stroke pre-
sentation. Secondary outcome were cardiovascular events,
requiring hospitalization, and death.
3. Statistical Analysis
Patients were divided for analysis into subgroups according
to perioperative characteristics and were compared with
respect to the occurrence of postoperative neurologic events
or NIHSS score variation (≥1).
Statistical analysis was performed with chi-square test
and Mann-Whitney test.
4. Results
From February 2003 to February 2011 we treated “early” 28
patients with carotid disease, for a total of 16 TEA (57%)
and 12 CAS (43%). A summary of the clinical results for all
patients group are given in Table 1. The mean age was 70
years (min 60, max 80) in group A and 75 years (min 70,
Table 3
NIHSS
surgical endovascular P value∗
At admission 7.4 4.4 <0.0001
∗
Chi-square test for trend.
max 80) in group B. The interval from symptom onset to
arrival at the emergency department did not differ between
groups. The prevalence of common vascular risk factors was
also similar between two groups. All patients had mild to
moderate neurologic deficit: median NIHSS score of 7.4 in
group A and 4.4 in group B (Table 3). This is the only
significant difference between the two groups. At admission,
early signs of cerebral ischemia were present at CT or MR
imaging in 10 (62.5%) of 16 patients in group A and in 7
(58%) of 12 patients of group B. The mean grade of stenosis
was 77.5% (from 70 to 85) for group A and 75% (from 70 to
80) for group B. Type of plaque at ECD was I in 5 cases, II in
5 cases, III in 3 cases, IV in 1 cases, and V in 2 cases in group
A. Type of plaque at ECD was I in 1 case, II in 3 cases, III in 7
cases, IV in 1 cases, and V in 0 cases in group B. TCD showed
relevant MES in 4 patients of group A and in all patients of
the group B. TCD depicted 16 patients with possible clamp
ischemia (8 in group A and 9 in group B). The CT or MR
imaging revealed 4 cases of contraindication to endovascular
femoral procedure (Leriche, tortuosity, and hostile arch).
Group A. Successful CEA was achieved in all cases (100%).
No intraprocedural neurologic complication occurred in
all but two. Procedural success, defined as absence of new
cerebrovascular events at discharge (including major stroke,
minor stroke, or TIA) was assessed at 87.45%. One female
and one male patient with crescendo TIA experienced an in-
hospital new neurologic event: stroke due to hemorrhagic
transformation of ischemic lesion. A Pruitt Inahara shunt
has been used in one patient. These patients died one month
after coma. Other nonneurological adverse event was one
acute myocardial infarction (AMI). An haematoma drainage
in the postoperative period was never necessary. The post-
operative NIHSS score at hospital discharge showed that
in 10/16 patients (62.5%) the neurological deficit improved
(decrease of NIHSS score >1), in 4/16 patients (25%) the
NIHSS score remained unchanged (decrease of NIHSS score
<1), and in 2 cases (12.5%) the neurological deficit showed
an impairment (coma). At 30 days NIHSS score showed that
in 11/16 patients (68.7%) the neurological deficit improved
(decrease of NIHSS score >1), in 4/16 patients (25%) the
NIHSS score remained unchanged (decrease of NIHSS score
<1), and in 2 cases (12.5%) the neurological deficit showed
an impairment (coma) (Tables 4 and 5).
No new ischemic lesions were detected by CT or MR
postoperative imaging although the NIHSS preoperative
score was significantly higher than in group B.
Group B. Successful CAS was achieved in all cases (100%).
In 8 cases a Boston Scientific Carotid Wallstent, in 3 cases an
Invatec Cristallo Ideale stent, and in 1 case an EV3 Protégé
RX carotid stent were implanted.
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Table 4
Parameter
Surgical
group
Endovascular
group
P
value∗
Number of patients 16 12
Early neurological results
Improvement (>1 NIHSS) 10 (63.5%) 9 (75%) 0.15
Stable 4 (25%) 0
Impairment (<1 NIHSS) 2 (12.5%) 3 (25%)
∗
Chi-square test for trend.
Table 5
NIHSS
At admission Postoperative P value∗
Surgical group 7.4 5.5 0.21
Endovascular group 4.4 3.4 0.36
∗
Mann-Whitney test.
No intraprocedural neurologic complication occurred,
while the minor complications that occurred during the
procedure were ICA vasospasm in 2/12 cases (16%) and
severe bradicardia and hypotension in 1/12 case (8%). Pro-
cedural success, defined as absence of new cerebrovascular
events at discharge (including major stroke, minor stroke,
or TIA) was assessed at 76%. Three patients experienced
an in-hospital new neurologic event (2 minor stroke 16%;
1 stroke 8%). Other nonneurological adverse events were a
persistent bradicardia and an AMI. The postoperative NIHSS
score at hospital discharge showed that in 8/12 patients
(66%) the neurological deficit improved (decrease of NIHSS
score >1), in 1/12 patients (8%) the NIHSS score remained
unchanged (decrease of NIHSS score <1) and in 3/12 cases
(24%) the neurological deficit showed an impairment (2
minor strokes 16%; 1 stroke 8%), in two cases without new
ischemic cerebral lesions. In 3 patients new ischemic lesions
were detected by CT or MR postoperative imaging, 2 of these
were asymptomatic although the NIHSS preoperative score
was significantly lower than in group A.
At 90 days NIHSS score showed that in 9/12 patients
(75%) the neurological deficit improved (decrease of NIHSS
score >1) and in 3/12 cases (24%) the neurological deficit
showed an impairment (2 minor strokes 16%; 1 stroke 8%)
(Tables 4 and 5).
5. Discussion
This study demonstrates the safety and the efficacy of early
CEA or CAS after TIA (within 24–48 hours) or stroke (within
14–28 days).
Effective and early management of patients with acute
symptoms due to carotid stenosis is still the subject of
debate. The inability to predict who is at higher early risk
of a recurrent stroke after a cerebrovascular event (TIA or
stroke) may explain the variation in management of acute
stroke comparing physician to physician and institution to
institution [12].
Improving outcomes of carotid surgery have recently
focused on the appropriate timing of carotid intervention in
the setting of new-onset neurological deficit. The increased
risks of reperfusion injury and conversion to hemorrhagic
infarction have led to the historical recommendation of
delayed CEA in those presenting with acute stroke [15–
17]. However, several high-volume centers have documented
the safety and efficacy of early intervention in preventing
recurrent strokes in carefully selected patients [18, 19].
More specifically, patients presenting with fluctuating and
potentially reversible neurological deficits may benefit from
the removal of an embolic source and/or salvage the at-risk
areas of the brain [18, 20]. Comparing medical therapy to
surgical intervention in those presenting with nondisabling
stroke and TIA, nonoperative therapy carried a 54% rate
of combined death and worsening neurological condition
whereas the combined death and stroke rate in the surgical
group was 7% [21]. The reported stroke risks highlight how
early removal of the carotid plaque, that is considered to be
the embolic source, could be crucial in stroke prevention
[12]. Rothwell et al. [22] have recently analyzed pooled
data from the European Carotid Surgery Trial and North
American Symptomatic Carotid Endarterectomy Trial (a
total of 5893 patients). The analysis of long-term stroke
prevention (per 1000 CEAs at 5 years), in relation to
the delay in surgery, clearly showed that benefit from
surgery decreased rapidly with time elapsed since the last
neurological symptoms. Profit from endarterectomy seems
to depend not only on the degree of carotid stenosis, but
also on delay in surgery. Recent data have conclusively shown
that patients benefit when intervention is performed within
2 weeks from the index event in order to prevent recurrent
stroke, even if the procedural risk may be higher [4, 22]. The
SPREAD guidelines also clearly state that carotid surgery is
recommended as early as possible—within 2 weeks of the
event—for patients with TIA, minor stroke, or stabilized
neurological deficit with normal CT scanning or minimal
lesions (Grade A recommendation) [23]. In a prospective
study of patients presenting with acute symptomatic high-
grade internal carotid artery stenosis, the Oxford Vascular
Study Group recently observed that for patients with TIA
the 7-day, 30-day, and 3-month risks of stroke were 8%,
12%, and 17% respectively, while for patients presenting with
minor stroke (NIH stroke score <3) parallel data were 12%,
15%, and 19% [24]. These data suggest that acute stroke
or TIA should be considered as medical emergencies that
require rapid evaluation and rapid targeting of treatment.
The decision to proceed with an urgent intervention for
those presenting with acute neurological deficit is challeng-
ing and requires very careful attention. Rothwell et al. in 2007
have reported a prospective study that shows how an early
treatment (medical and/or surgical) of all patients presenting
with TIA or minor stroke can prevent about 80% of early
recurrent stroke [25]. Although the timing of intervention
may be debatable, the mode of intervention is even more
controversial.
We demonstrated the safety of CEA in this series of high-
risk/complex carotid cases enrolled and treated soon after
the onset of symptoms, as shown by the little percentage
of neurological complications during the procedure, a high
procedural success rate, and the very low rate of minor
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cerebrovascular events in the postoperative period. The
clinical outcome at 1 month of a 12.5% stroke/mortality rate
and 12.5% rate for all neurological events is satisfactory con-
sidering the very high-risk profile of the patient population.
An Italian multicenter study, Surgical Treatment of Acute
Cerebral Ischemia (STACI) [26], has recently shown that
patients, whose neuroimaging studies document a recent,
limited cerebral infarction in the early hours after a stroke,
can safely undergo very early CEA (1.5 days after the stroke).
This study underlines that if patients are strictly selected for
early CEA after an acute stroke, early surgery gains similar
results to elective surgery. Capoccia et al. in a recent study
suggest that minimizing the time for intervention not only
reduces the risk of recurrence but can also improve neuro-
logic outcome [27]. Gertler et al. [18] reviewed the results
of CEA in neurologically unstable patients with significant
carotid stenosis and presenting with crescendo TIA contin-
uing despite heparin or stroke in evolution. The condition
of all but one (2.7%) was either improved or stabilized
after operation. They recommended early intervention of
neurologically unstable patients to improve the outcome in
those patients. Huber et al. [28] demonstrated, through pre-
and postoperative diffusion-weighted (DW) and perfusion-
weighted (PW) MR, a reduction of the cerebral ischemic
lesion in the patients operated on. Speculatively, these data
might suggest a role of surgical reperfusion in rapidly
improving the clinical course even 24 to 48 hours after stroke
onset. Obviously, this speculation would need to be tested in
large number of patients studied with DW and PW MR.
In the absence of scientific proof from conclu-
sive randomized trials, and despite the negative results
of Endarterectomy versus Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S) [29] and
Stent-Protected Angioplasty versus Carotid Endarterectomy
(SPACE) [30, 31] favoring CEA over CAS in symptomatic
severe carotid artery stenosis, many interventionalists con-
sider both modalities to be equivalent [21]. With grow-
ing experience in endovascular treatment, CAS has been
proposed as an alternative to CEA, but data regarding the
outcome of patients with acute stroke undergoing urgent
endovascular surgery are still scarce. The main concern about
CAS in urgent cases is that while with CEA the plaque is
completely removed, after stenting it is only remodelled and
its stabilization is essential to avoid later embolic events [12].
We demonstrated the safety of CAS in this series of high-
risk/complex carotid cases enrolled and treated soon after
the onset of symptoms, as shown by the little percentage
of neurological complications during the procedure, a high
procedural success rate, and the very low rate of minor cere-
brovascular events in the postoperative period. The clinical
outcome at 1 month of a 0% stroke/mortality rate and 25%
rate for all neurological events are satisfactory considering
the very high-risk profile of the patient population. In this
study an open-cell stent was used in one out of 12 cases.
Setacci et al. [12] enrolled 57 patients in a prospective
registry studying the role of protected CAS in those present-
ing with symptomatic carotid lesion. Twenty-four patients
(42%) had TIA and were intervened upon within 24 to 48
hours from the last episode, while the remaining 33 (58%)
patients who presented with stroke and intervention were
delayed to 14 to 30 days. At 30 days, 1 patient died (1.7%) and
2 suffered postoperative TIAs (3.5%). They concluded that
CAS with embolic protection is a feasible and safe alternative
to CEA in the acute setting.
An important consideration during CAS is the concern
of scaffolding of vulnerable plaques and the risk of distal
embolization. The role of stent designs as well the use
embolic protection device will remain to be determined by
the outcome of ongoing and yet-to-start randomized trials
[21]. We wait for the results of Submarine II Registry to
evaluate the safety of CAS in symptomatic stroke patients
using either a closed- or an open-cell stent [12]. At present,
sophisticated imaging techniques such as pixel density
analysis and elastography at duplex examination [32, 33],
magnetic resonance imaging for tissue characterization [34,
35], or local temperature probes [36, 37] all hold promise for
the noninvasive identification of vulnerable plaques and the
detection of silent atheroma.
Mussa et al. [21] obtained a confirmatory study in all
patients undergoing CEA, and in the last few years, they
have relied on images from MRA and CTA to guide their
indications and more remarkably, the mode of intervention.
A potential advantage of MRA and CTA over conventional
angiography would be their ability to image the residual
lumen and may aid the characterization of “vulnerable”
plaque to evaluate stroke risk. Furthermore, with the increas-
ing role of carotid angioplasty and stenting, these imaging
modalities provide a detailed map for the aortic arch and the
cervical course of the internal carotid artery.
In our study of the 28 patients, 20 (71%) showed either
total or partial resolution of symptoms. One patient with
TIA deteriorated after intervention. Our combined death
and stroke rate of 17.8% is comparable with that of others.
In conclusion, our study demonstrated that early treat-
ment with CEA or protected carotid stenting is both feasible
and safe in selected patients with first episode or recurrent
TIA or minor stroke. This preliminary study in a limited
series of patients revealed that an urgent endovascular
approach has a satisfactory outcome considering the very
high-risk profile of the patient population, but CEA remains
the gold standard.
Given that the ABCD2 score seems to constitute a valu-
able tool able to identify in the ED the subgroup of TIA or
minor stroke patients which is at greatest need for emergent
evaluation and effective treatment, the applicability of the
former score in clinical practice may raise certain potential
therapeutic implications.
Appendix
ABCD2 Score
For the needs of the present study, an investigator (C.
Fantozzi) blinded to the follow-up events retrospectively
reviewed both the ED and hospital records of all 28 patients.
The 7-point ABCD2 score (age (<60 years = 0, ≥60 years
= 1); BP (systolic ≤140 mm Hg and diastolic ≤90 mm Hg =
0, systolic >140 mm Hg and/or diastolic >90 mm Hg = 1);
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clinical features (unilateral weakness = 2, speech disturbance
without weakness = 1, other symptom = 0); duration
of symptoms (<10 minutes = 0, 10 to 59 minutes = 1,
≥60 minutes = 2) and diabetes [1] was computed in 20
cases. Clinical features were categorized as motor weakness
(focal, usually unilateral, weakness of one or more of face,
arm, hand, or leg) versus speech disturbance (defined as
dysarthria or dysphasia or both) versus all other symptoms
(numbness, change in vision, dizziness or vertigo, and gait
disturbance) according to the OCSP definition of the ABCD2
score. Seven patients with unavailable BP recordings (n = 2)
or duration of TIA symptoms (n = 5) at the ED records were
excluded from further evaluation.
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